STEP-UP: Higher radiation for recurrent rectal cancer
This trial tests giving a higher dose of radiation to people whose rectal cancer has come back in the pelvis after surgery and cannot be removed. It aims to see if more radiation can help control the tumor when surgery is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your rectal cancer has returned in the pelvis after you had surgery for it, and doctors agree it cannot be fully removed (or you have chosen not to have surgery).
- You have no cancer spread that needs urgent drug treatment, or only a few small spots of spread that do not need treatment right away.
- You can carry out daily activities with little or no help (WHO performance score 0-2).
- You have not had radiation therapy in the last 6 months.
- You have not received certain targeted drugs (bevacizumab, panitumumab, or cetuximab) within 6 weeks before starting radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
This trial tests whether giving radiation (with or without chemo) before surgery can help people whose rectal cancer has come back in the pelvis. It aims to make the tumor removable and improve outcomes.
This trial tests an “induction chemotherapy” treatment before surgery for people whose rectal cancer has come back in the local area. The goal is to shrink/control the cancer early and improve outcomes after treatment.
This trial tests targeted radiation (SBRT) for people whose rectal cancer has come back in the pelvis and cannot be surgically removed. The goal is to see if this focused radiation can control the tumor with fewer side effects.
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
Hear when a new Locally Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.